WO2006050959A3 - Molecules which promote hematopoiesis - Google Patents

Molecules which promote hematopoiesis Download PDF

Info

Publication number
WO2006050959A3
WO2006050959A3 PCT/EP2005/012075 EP2005012075W WO2006050959A3 WO 2006050959 A3 WO2006050959 A3 WO 2006050959A3 EP 2005012075 W EP2005012075 W EP 2005012075W WO 2006050959 A3 WO2006050959 A3 WO 2006050959A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
promote hematopoiesis
peptides
hematopoiesis
promote
Prior art date
Application number
PCT/EP2005/012075
Other languages
French (fr)
Other versions
WO2006050959A2 (en
Inventor
Hans-Georg Frank
Franz-Peter Bracht
Udo Haberl
Andreas Rybka
Original Assignee
Aplagen Gmbh
Hans-Georg Frank
Franz-Peter Bracht
Udo Haberl
Andreas Rybka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/041,207 external-priority patent/US7589063B2/en
Priority to EP05819212A priority Critical patent/EP1812461A2/en
Priority to US11/667,290 priority patent/US20090118195A1/en
Priority to CA002586915A priority patent/CA2586915A1/en
Priority to EA200701031A priority patent/EA200701031A1/en
Priority to AU2005303887A priority patent/AU2005303887A1/en
Priority to JP2007540582A priority patent/JP2008519589A/en
Priority to BRPI0518025-2A priority patent/BRPI0518025A/en
Priority to MX2007005640A priority patent/MX2007005640A/en
Application filed by Aplagen Gmbh, Hans-Georg Frank, Franz-Peter Bracht, Udo Haberl, Andreas Rybka filed Critical Aplagen Gmbh
Publication of WO2006050959A2 publication Critical patent/WO2006050959A2/en
Priority to EA200800109A priority patent/EA200800109A1/en
Priority to US11/917,991 priority patent/US20100145006A1/en
Priority to CA002648732A priority patent/CA2648732A1/en
Priority to EP06754540A priority patent/EP1907417A2/en
Priority to PCT/EP2006/006097 priority patent/WO2006136450A2/en
Priority to BRPI0611745-7A priority patent/BRPI0611745A2/en
Priority to JP2008517435A priority patent/JP2008546732A/en
Publication of WO2006050959A3 publication Critical patent/WO2006050959A3/en
Priority to IL182843A priority patent/IL182843A0/en
Priority to NO20072856A priority patent/NO20072856L/en
Priority to IL188153A priority patent/IL188153A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to EPO mimetic peptides and special synthesis methods for the production of multivalent and/or supravalent peptides.
PCT/EP2005/012075 2004-11-10 2005-11-10 Molecules which promote hematopoiesis WO2006050959A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP05819212A EP1812461A2 (en) 2004-11-10 2005-11-10 Molecules which promote hematopoiesis
US11/667,290 US20090118195A1 (en) 2004-11-10 2005-11-10 Molecules Which Promote Hematopoiesis
CA002586915A CA2586915A1 (en) 2004-11-10 2005-11-10 Molecules which promote hematopoiesis
EA200701031A EA200701031A1 (en) 2004-11-10 2005-11-10 MOLECULES ASSISTING HEMATOPESIS
AU2005303887A AU2005303887A1 (en) 2004-11-10 2005-11-10 Molecules which promote hematopoiesis
JP2007540582A JP2008519589A (en) 2004-11-10 2005-11-10 Molecules that promote hematopoiesis
BRPI0518025-2A BRPI0518025A (en) 2004-11-10 2005-11-10 molecules that promote hematopoiesis
MX2007005640A MX2007005640A (en) 2004-11-10 2005-11-10 Molecules which promote hematopoiesis.
JP2008517435A JP2008546732A (en) 2005-06-23 2006-06-23 Polyvalent compound
EA200800109A EA200800109A1 (en) 2005-06-23 2006-06-23 SUPRAVALENT CONNECTIONS
BRPI0611745-7A BRPI0611745A2 (en) 2005-06-23 2006-06-23 supravalent compounds
US11/917,991 US20100145006A1 (en) 2005-06-23 2006-06-23 Supravalent compounds
CA002648732A CA2648732A1 (en) 2005-06-23 2006-06-23 Supravalent compounds
EP06754540A EP1907417A2 (en) 2005-06-23 2006-06-23 Supravalent compounds
PCT/EP2006/006097 WO2006136450A2 (en) 2005-06-23 2006-06-23 Supravalent compounds
IL182843A IL182843A0 (en) 2004-11-10 2007-04-29 Peptides that bind to the erythropoietin receptor, compounds incorporating the same, methods for the preparation thereof and pharmaceutical compositions containing the same
NO20072856A NO20072856L (en) 2004-11-10 2007-06-05 Molecules that promote hematopoiesis
IL188153A IL188153A0 (en) 2005-06-23 2007-12-16 Supravalent peptide compounds and processor for the preparation thereof

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
DE102004054422 2004-11-10
DE102004054422.0 2004-11-10
EP04029536.2 2004-12-14
EP04029536 2004-12-14
US11/041,207 2005-01-25
US11/041,207 US7589063B2 (en) 2004-12-14 2005-01-25 Molecules which promote hematopoiesis
EP05002113.8 2005-02-02
EP05002113 2005-02-02
EP05012637 2005-06-13
EP05012637.4 2005-06-13
EP05013594 2005-06-23
EP05013594.6 2005-06-23
EP05020035.1 2005-09-14
EP05020035 2005-09-14

Publications (2)

Publication Number Publication Date
WO2006050959A2 WO2006050959A2 (en) 2006-05-18
WO2006050959A3 true WO2006050959A3 (en) 2006-12-21

Family

ID=36336855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/012075 WO2006050959A2 (en) 2004-11-10 2005-11-10 Molecules which promote hematopoiesis

Country Status (7)

Country Link
EP (1) EP1812461A2 (en)
JP (1) JP2008519589A (en)
KR (1) KR20070092706A (en)
AU (1) AU2005303887A1 (en)
CA (1) CA2586915A1 (en)
NO (1) NO20072856L (en)
WO (1) WO2006050959A2 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2648732A1 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
BRPI0709014A2 (en) * 2006-03-09 2011-06-21 Aplagen Gmbh modified molecules that promote hematopoiesis
EP2018835B1 (en) 2007-07-09 2014-03-05 Augustinus Bader Agent-eluting plaster
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
WO2009055014A2 (en) 2007-10-23 2009-04-30 Nektar Therapeutics Al, Corporation Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
JP2009191056A (en) * 2008-02-15 2009-08-27 Affymax Inc Therapy of disorder mediated by anti-erythropoietin antibody using epo receptor agonist based on synthetic peptide
US8853185B2 (en) * 2008-04-09 2014-10-07 Cornell University Coferons and methods of making and using them
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
US9771345B2 (en) 2009-10-07 2017-09-26 Cornell University Coferons and methods of making and using them
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
RS54291B2 (en) 2010-06-07 2023-12-29 Amgen Inc Drug delivery device
ES2632164T3 (en) 2010-07-06 2017-09-11 Augustinus Bader Topical application of erythropoietin for use in the treatment of corneal lesions
MX341790B (en) 2011-03-31 2016-09-02 Amgen Inc Vial adapter and system.
PL2699293T3 (en) 2011-04-20 2019-08-30 Amgen Inc. Autoinjector apparatus
DK3045189T3 (en) 2011-10-14 2018-06-18 Amgen Inc Injector and mounting method
ES2780395T3 (en) 2012-11-21 2020-08-25 Amgen Inc Drug delivery device
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
JP6768501B2 (en) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド Drug cassettes, automatic injection machines, and automatic injection machine systems
KR102218494B1 (en) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 Anti-hepcidin antibodies and uses thereof
BR112015024282B1 (en) 2013-03-22 2022-05-17 Amgen Inc Injector and injector mounting method
CN105873626A (en) 2013-10-24 2016-08-17 美国安进公司 Injector and method of assembly
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
JP6640113B2 (en) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド Auto-injector with impact reducing element
CA2949846C (en) 2014-06-03 2023-09-05 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
MX2021014323A (en) 2014-10-14 2023-02-02 Amgen Inc Drug injection device with visual and audio indicators.
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (en) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (en) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP2020503976A (en) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド Injection device and associated methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7280189B2 (en) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
CN110709121B (en) 2017-06-08 2022-06-24 安进公司 Torque-driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (en) 2017-06-22 2020-04-29 Amgen Inc REDUCTION OF IMPACTS / SHOCKS OF ACTIVATION OF A DEVICE
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
MA49626A (en) 2017-07-21 2020-05-27 Amgen Inc GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES
JP2020528296A (en) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド Drug delivery device with gear module and related assembly method
MA49676A (en) 2017-07-25 2020-06-03 Amgen Inc DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
IL272636B1 (en) 2017-10-06 2024-06-01 Amgen Inc Drug delivery device with interlock assembly and related method of assembly
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
CN116832271A (en) 2017-11-10 2023-10-03 安进公司 Plunger for a drug delivery device
JP2021503311A (en) 2017-11-16 2021-02-12 アムジエン・インコーポレーテツド Auto-injector with stall and end point detection
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
CN112469454B (en) 2018-07-24 2024-01-26 安进公司 Delivery device for administering a drug
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
MA53724A (en) 2018-09-24 2021-12-29 Amgen Inc INTERVENTIONAL DOSING SYSTEMS AND METHODS
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (en) 2018-10-02 2023-09-22 安进公司 Injection system for drug delivery with internal force transfer
AR116607A1 (en) 2018-10-05 2021-05-26 Amgen Inc DRUG ADMINISTRATION DEVICE WITH DOSE INDICATOR
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
AR116704A1 (en) 2018-10-15 2021-06-02 Amgen Inc DRUG ADMINISTRATION DEVICE WITH CUSHIONING MECHANISM
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
MX2021012557A (en) 2019-04-24 2021-11-12 Amgen Inc Syringe sterilization verification assemblies and methods.
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106954A (en) * 1989-07-26 1992-04-21 Behringwerke Aktiengesellschaft Erythropoietin (epo) peptides
WO1996040749A1 (en) * 1995-06-07 1996-12-19 Johnson & Johnson Corporation Compounds and peptides that bind to the erythropoietin receptor
WO2004002424A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106954A (en) * 1989-07-26 1992-04-21 Behringwerke Aktiengesellschaft Erythropoietin (epo) peptides
WO1996040749A1 (en) * 1995-06-07 1996-12-19 Johnson & Johnson Corporation Compounds and peptides that bind to the erythropoietin receptor
WO2004002424A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHNSON D ET AL: "Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, no. 11, 1998, pages 3699 - 3710, XP002147315, ISSN: 0006-2960 *
JOHNSON D L ET AL: "AMINO-TERMINAL DIMERIZATION OF AN ERYTHROPOIETIN MIMETIC PEPTIDE RESULTS IN INCREASED ERYTHROPOIETIC ACTIVITY", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 4, no. 12, 1997, pages 939 - 950, XP000886469, ISSN: 1074-5521 *
WRIGHTON N C ET AL: "INCREASED POTENCY OF AN ERYTHROPOIETIN PEPTIDE MIMETIC THROUGH COVALENT DIMERIZATION", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 15, November 1997 (1997-11-01), pages 1261 - 1265, XP000749524, ISSN: 1087-0156 *
WRIGHTON N C ET AL: "SMALL PEPTIDES AS POTENT MIMETICS OF THE PROTEIN HORMONE ERYTHROPOIETIN", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 273, 26 July 1996 (1996-07-26), pages 458 - 463, XP002021036, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
JP2008519589A (en) 2008-06-12
WO2006050959A2 (en) 2006-05-18
AU2005303887A1 (en) 2006-05-18
NO20072856L (en) 2007-08-08
EP1812461A2 (en) 2007-08-01
CA2586915A1 (en) 2006-05-18
KR20070092706A (en) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2006050959A3 (en) Molecules which promote hematopoiesis
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
WO2006029094A3 (en) Erythropoietin derivatives with altered immunogenicity
WO2005062916A3 (en) Methods for generating multimeric molecules
WO2007082923A3 (en) Use of protein microbeads in cosmetics
PT1913001E (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
WO2006110651A3 (en) Reflective displays and processes for their manufacture
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
WO2005118564A3 (en) Methods for the synthesis of milnacipran and congeners thereof
EP1869623A4 (en) Authentication of merchandise units
WO2007139871A3 (en) Methods and materials for making simvastatin and related compounds
WO2006081562A3 (en) Synthesis of aryl pyrrolidones
WO2005078074A3 (en) Protease variants
WO2007001962A3 (en) Systems and methods for generating biological material
WO2006116703A3 (en) Methods and models for stress-induced analgesia
GB0426160D0 (en) Production of proteins
WO2004075021A3 (en) Molecular modeling methods
WO2006135885A8 (en) Assortment of antiperspirants having two or more product performance characteristics
WO2007014076A3 (en) Methods of producing modified assembly lines and related compositions
IL183106A0 (en) Production of proteins
IL187688A0 (en) Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis
WO2008083191A3 (en) Radiofluorination methods
EG24324A (en) Production of hydrocarbon fuel
WO2005003157A3 (en) Interferon variants with improved properties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 182843

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2586915

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007540582

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005640

Country of ref document: MX

Ref document number: 200580038438.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005819212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005303887

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 555650

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020077012937

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2496/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200701031

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005303887

Country of ref document: AU

Date of ref document: 20051110

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005303887

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005819212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11667290

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0518025

Country of ref document: BR